JP2022548689A5 - - Google Patents

Info

Publication number
JP2022548689A5
JP2022548689A5 JP2022517372A JP2022517372A JP2022548689A5 JP 2022548689 A5 JP2022548689 A5 JP 2022548689A5 JP 2022517372 A JP2022517372 A JP 2022517372A JP 2022517372 A JP2022517372 A JP 2022517372A JP 2022548689 A5 JP2022548689 A5 JP 2022548689A5
Authority
JP
Japan
Prior art keywords
crystal according
degrees
powder
ray diffraction
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548689A (ja
JP7706166B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051563 external-priority patent/WO2021055797A1/en
Publication of JP2022548689A publication Critical patent/JP2022548689A/ja
Publication of JP2022548689A5 publication Critical patent/JP2022548689A5/ja
Application granted granted Critical
Publication of JP7706166B2 publication Critical patent/JP7706166B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517372A 2019-09-18 2020-09-18 タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤 Active JP7706166B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902322P 2019-09-18 2019-09-18
US62/902,322 2019-09-18
PCT/US2020/051563 WO2021055797A1 (en) 2019-09-18 2020-09-18 Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Publications (3)

Publication Number Publication Date
JP2022548689A JP2022548689A (ja) 2022-11-21
JP2022548689A5 true JP2022548689A5 (cg-RX-API-DMAC10.html) 2023-09-25
JP7706166B2 JP7706166B2 (ja) 2025-07-11

Family

ID=72717922

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022517372A Active JP7706166B2 (ja) 2019-09-18 2020-09-18 タンパク質アルギニンメチルトランスフェラーゼ5(prmt5)の選択的阻害剤

Country Status (12)

Country Link
US (2) US12414953B2 (cg-RX-API-DMAC10.html)
EP (1) EP4031555A1 (cg-RX-API-DMAC10.html)
JP (1) JP7706166B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220065811A (cg-RX-API-DMAC10.html)
CN (1) CN114829370B (cg-RX-API-DMAC10.html)
AU (1) AU2020349553B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022004630A2 (cg-RX-API-DMAC10.html)
CA (1) CA3154566A1 (cg-RX-API-DMAC10.html)
IL (1) IL291417B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022003340A (cg-RX-API-DMAC10.html)
WO (1) WO2021055797A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202203680B (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116211869B (zh) * 2022-12-07 2023-08-01 浙江省肿瘤医院 含dna损伤修复抑制剂的药物混合物及混合方法、用途
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
AR081626A1 (es) * 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2015200680A2 (en) * 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
AU2015301196A1 (en) * 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
MA41827A (fr) * 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI730980B (zh) * 2015-08-26 2021-06-21 比利時商健生藥品公司 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物
CN108884108B (zh) 2016-03-10 2021-08-31 詹森药业有限公司 用于用作prmt5抑制剂的取代核苷类似物
WO2017206904A1 (zh) * 2016-06-02 2017-12-07 上海海雁医药科技有限公司 Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用
WO2017218802A1 (en) * 2016-06-15 2017-12-21 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
BR112019006414A2 (pt) * 2016-10-03 2019-06-25 Janssen Pharmaceutica Nv análogos de carbanucleosídeos de sistema de anel monocíclico e bicíclico substituídos para uso como inibidores de prmt5
KR101785870B1 (ko) 2016-11-03 2017-10-13 한규락 오르골 장치
MA49840A (fr) * 2017-08-09 2020-06-17 Prelude Therapeutics Inc Inhibiteurs sélectifs de la protéine arginine méthyltransférase 5 (prmt5)
EP3700906A1 (en) * 2017-10-26 2020-09-02 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
CA3092357A1 (en) 2018-03-14 2019-09-19 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Similar Documents

Publication Publication Date Title
JP7546548B2 (ja) 組み合わせ療法
JP2017061547A5 (cg-RX-API-DMAC10.html)
JP2022520382A5 (cg-RX-API-DMAC10.html)
JP2022509724A (ja) 組み合わせ療法
TW200924786A (en) Certain compounds, compositions and methods
JP2022511029A5 (cg-RX-API-DMAC10.html)
JP2014502641A5 (cg-RX-API-DMAC10.html)
WO2018210296A1 (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
JP2021524835A5 (cg-RX-API-DMAC10.html)
IL277263B2 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
TW202313050A (zh) 組合療法
CN107163027B (zh) 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用
JP2024520630A5 (cg-RX-API-DMAC10.html)
IL291417B1 (en) Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US20250152569A1 (en) Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent
JP2022535850A5 (cg-RX-API-DMAC10.html)
JP2020514344A5 (cg-RX-API-DMAC10.html)
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
TW201904577A (zh) N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
JP2024534517A5 (cg-RX-API-DMAC10.html)
JP2020536048A5 (cg-RX-API-DMAC10.html)
JP2022521491A5 (cg-RX-API-DMAC10.html)
JP2013537901A5 (cg-RX-API-DMAC10.html)
JP2023530786A5 (cg-RX-API-DMAC10.html)
EP4554586A1 (en) Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer